PR Newswire: news distribution, targeting and monitoring
2014

Epiomed and NASA Sign Space Act Agreement

Share with Twitter Share with LinkedIn

IRVINE, Calif. , Oct. 12, 2012 /PRNewswire/ -- Epiomed Therapeutics, Inc. ("Epiomed") announced today that it has entered into a Reimbursable Space Act Agreement (SAA) with the National Aeronautics and Space Administration (NASA) Lyndon B. Johnson Space Center in Houston, Texas for the development, distribution, manufacture and market release of INSCOP, an intra-nasal scopolamine product. A gel formulation of INSCOP has previously been developed and tested under a SAA between NASA-Johnson Space Center and the Naval Aerospace Medical Research Laboratory, Pensacola, FL (NAMRL).  Results from the NAMRL / NASA trial have been published in the journal Aviation, Space, and Environmental Medicine, and suggest that INSCOP is a fast-acting, reliable, operationally suitable, countermeasure for prophylaxis and treatment of motion sickness with a great potential for rescue treatment. In 2010, NAMRL disestablished and became part of the Naval Medical Research Unit – Dayton, OH (NAMRU-D). NAMRU-D is currently working a Cooperative Research and Development Agreement (CRADA) with Epiomed to test an aqueous formulation of INSCOP (INSCOP Spray). The aim of INSCOP Spray development is to offer a fast acting formulation with no notable side-effects experienced with currently marketed formulations of the drug. Epiomed will take responsibility for further development and commercialization of INSCOP, assisted by NASA-HH&P (Human Health & Performance Directorate) technology, and assume sponsorship of the IND (Investigational New Drug) from NASA under the SAA. David R. Helton, President and CEO of Epiomed, said "NASA and NAMRL did ground breaking work with INSCOP gel. Now Epiomed is dedicated to complete the required clinical evaluations in collaboration with NASA and NAMRU-D to facilitate market release of INSCOP Spray." 

About Epiomed Therapeutics

Epiomed Therapeutics, Inc. is a privately-held pharmaceutical company engaged in the discovery, and development of novel central nervous system (CNS) drugs, with a primary focus on anti-emetics (anti-vomiting and anti-nausea), anxiolytics and performance sustainment.

About Human Health & Performance Directorate (HH&P) – Houston

HH&P is dedicated to optimize human health and productivity for space exploration by conducting research and developing path changing technologies to assure mission success, optimize human health and productivity in space and on Earth (http://www.nasa.gov/offices/NHHPC/index.html).

For further information, call 1-949-398-7359, or visit www.epiomed.com.

Safe Harbor: This press release contains certain forward-looking information about Epiomed Therapeutics, Inc., which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995.

Contact:
David R. Helton
President, CEO and CSO
Epiomed Therapeutics, Inc.
949-398-7359

SOURCE Epiomed Therapeutics, Inc.



RELATED LINKS
http://www.epiomed.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 
Area to test

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release